[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634159":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":11,"studyPopulation":11,"armGroups":31,"interventions":48,"overallOfficials":57,"centralContacts":61,"locations":67,"responsibleParty":133,"collaborators":11,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":11,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":11,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Sarepta Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)",null,"Baseline through Week 24",[14,17,19],{"measure":15,"description":11,"timeFrame":16},"Plasma Concentration of SRP-1005","Baseline through Day 17",{"measure":18,"description":11,"timeFrame":16},"Urine Concentration of SRP-1005",{"measure":20,"description":11,"timeFrame":12},"Cerebrospinal Fluid Concentration of SRP-1005",{"allocation":22,"interventionModel":23,"interventionModelDescription":11,"primaryPurpose":24,"observationalModel":11,"timePerspective":11,"maskingInfo":25},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":26,"maskingDescription":11,"whoMasked":27},"TRIPLE",[28,29,30],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[32,39,42,45],{"label":33,"type":34,"description":35,"interventionNames":36},"Cohort 1: SRP-1005 Dose 1","EXPERIMENTAL","Participants will receive SRP-1005 or placebo.",[37,38],"Drug: SRP-1005","Drug: Placebo",{"label":40,"type":34,"description":35,"interventionNames":41},"Cohort 2: SRP-1005 Dose 2",[37,38],{"label":43,"type":34,"description":35,"interventionNames":44},"Cohort 3: SRP-1005 Dose 3",[37,38],{"label":46,"type":34,"description":35,"interventionNames":47},"Cohort 4: SRP-1005 Dose 4",[37,38],[49,54],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":11},"DRUG","SRP-1005","Subcutaneous injection",[33,40,43,46],{"type":50,"name":55,"description":52,"armGroupLabels":56,"otherNames":11},"Placebo",[33,40,43,46],[58],{"name":59,"affiliation":5,"role":60},"Medical Director","STUDY_DIRECTOR",[62],{"name":63,"role":64,"phone":65,"phoneExt":11,"email":66},"Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4","CONTACT","1-888-SAREPTA (1-888-727-3782)","SareptAlly@sarepta.com",[68,87,102,118],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"Westmead Hospital","RECRUITING","Westmead","New South Wales","2145","Australia","AU",{"type":77,"coordinates":78},"Point",[79,80],150.98768,-33.80383,{"lat":80,"lon":79},[83,84],{"name":11,"role":64,"phone":11,"phoneExt":11,"email":66},{"name":85,"role":86,"phone":11,"phoneExt":11,"email":11},"Clement Loy","PRINCIPAL_INVESTIGATOR",{"facility":88,"status":70,"city":89,"state":11,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"New Zealand Brain Research Institute","Christchurch","8014","New Zealand","NZ",{"type":77,"coordinates":94},[95,96],172.63333,-43.53333,{"lat":96,"lon":95},[99,100],{"name":11,"role":64,"phone":11,"phoneExt":11,"email":66},{"name":101,"role":86,"phone":11,"phoneExt":11,"email":11},"Timothy Anderson, MD, FRACP",{"facility":103,"status":70,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Siloah AG","Gümligen","Canton of Bern","3073","Switzerland","CH",{"type":77,"coordinates":110},[111,112],7.50933,46.9345,{"lat":112,"lon":111},[115,116],{"name":11,"role":64,"phone":11,"phoneExt":11,"email":66},{"name":117,"role":86,"phone":11,"phoneExt":11,"email":11},"Michael Orth, Prof. Dr. med.",{"facility":119,"status":70,"city":120,"state":11,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"University Hospital of Wales","Cardiff","3AT","United Kingdom","UK",{"type":77,"coordinates":125},[126,127],-3.18,51.48,{"lat":127,"lon":126},[130,131],{"name":11,"role":64,"phone":11,"phoneExt":11,"email":66},{"name":132,"role":86,"phone":11,"phoneExt":11,"email":11},"Anne Rosser, Prof.",{"type":134,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634159","phase-1-a-first-in-human-study-of-the-effects-of-srp-1005-in-participants-with-huntingtons-disease-100634159",false,"NCT07536061","A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)","Key Inclusion Criteria:\n\n* Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.\n* Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3.\n* Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.\n\nKey Exclusion Criteria:\n\n* Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI).\n* Presence of other significant neurological or systemic illnesses.\n* Current, chronic or active human immunodeficiency virus, hepatitis B\u002FC.\n* Recent use of investigational agents or HTT-lowering therapies.\n* Uncontrolled psychiatric illness or substance use disorders.\n* Pregnancy or lactation.\n\nNote: Other inclusion\u002Fexclusion criteria apply.","ALL","21 Years","70 Years",{"count":146,"type":147},32,"ESTIMATED","INTERVENTIONAL",[150],"PHASE1","This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).",[153],"Huntington's Disease",[155,51,156,157],"Huntington's disease","Dose Escalation","First in Human","2026-09-03",{"date":160,"type":161},"2026-09-04","ACTUAL",{"date":163,"type":161},"2026-05-12",{"date":165,"type":147},"2027-11-30",{"name":5,"class":6},4]